VectorY Therapeutics has raised €74.5 million ($83.5 million) in new financing. The clinical-stage biotech develops vectorized antibody therapies for neurodegenerative diseases. New investors include Angelini Ventures, Invest-NL, and the European Investment Bank.
Funding details
Returning investors include Forbion, EQT Life Sciences, MRL Ventures, and Insight Partners. The company has also expanded the PIONEER-ALS study from 12 to 36 participants. Proceeds will support VTx-002 through key clinical milestones.
Company pipeline
VectorY is building a pipeline that includes programs for ALS, Huntington's disease, frontotemporal dementia, and Alzheimer's disease. Its platform combines AAV-based delivery, antibody engineering, and manufacturing. The company focuses on precision-targeted, durable therapies for neurodegenerative conditions.
Lead program details
VTx-002 targets pathological TDP-43, a protein that aggregates in up to 97% of ALS patients. The vectorized antibody is designed for sustained expression within the central nervous system. It is currently being evaluated in the global PIONEER-ALS Phase 1/2 study.
Next steps include the final readout of the PIONEER-ALS study. VectorY will also use the financing to advance VTx-003 for Huntington's disease. The company is enrolling participants across the U.S., Europe, and the U.K.